Amy Lee
About Amy Lee
Amy Lee is an Associate Director of Pharmacology at AbCellera, with extensive experience in drug development and pharmacology. She has held various leadership roles at organizations such as Arbutus Biopharma Corporation and Protiva Biotherapeutics, and holds both a BSc and MSc in Microbiology & Immunology from the University of British Columbia.
Current Role at AbCellera
Amy Lee serves as the Associate Director of Pharmacology at AbCellera, a position she has held since 2022. In this role, she focuses on pharmacological research and development, contributing her expertise in drug target selection and nucleic acid therapeutics. Her work involves overseeing projects that support product development and ensuring the generation of in vivo and in vitro activity and safety datasets.
Previous Experience at Arbutus Biopharma Corporation
Amy Lee held multiple roles at Arbutus Biopharma Corporation from 2008 to 2020. She began as a Research Director for Metabolic Programs and later transitioned to Senior Director positions, including In Vivo Pharmacology and Clinical Virology, as well as Infectious Disease Research. Her tenure included setting up animal models and biomarker assays for various disease areas, demonstrating her extensive experience in pharmacology and virology.
Experience at Protiva Biotherapeutics
Amy Lee worked at Protiva Biotherapeutics from 2001 to 2008, where she progressed from a Research Associate to a Research Scientist. During her time there, she contributed to the development of therapeutic solutions, gaining foundational experience in the biotherapeutics field.
Educational Background in Microbiology and Immunology
Amy Lee earned both her Bachelor of Science and Master of Science degrees in Microbiology and Immunology from The University of British Columbia. Her academic background provided her with a strong foundation in microbiological research and immunological principles, which she applies in her professional roles.
Expertise in Drug Development and Research
Amy Lee possesses expertise in drug target selection and siRNA design specifically for lipid nanoparticle-delivered nucleic acid therapeutics. She has experience in building and leading research teams, as well as setting up animal models and biomarker assays across various disease areas, including hepatitis B and oncology.